 [1m([0morchestrator-renal failure-AMBISOME[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes AMBISOME increase or decrease the risk of renal failure?[0m
 [1m([0morchestrator-renal failure-AMBISOME[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-AMBISOME[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-renal failure-AMBISOME[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does AMBISOME increase or decrease the risk of renal failure?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-renal failure-AMBISOME[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes AMBISOME increase or decrease the risk of renal failure?[0m
 [1m([0morchestrator-renal failure-AMBISOME[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-AMBISOME[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-renal failure-AMBISOME[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes AMBISOME increase or decrease the risk of renal failure?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does AMBISOME increase or decrease the risk of renal failure?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"AMBISOME"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: AMBISOME: adverse_reactions: Digestive System Anorexia, constipation, dry mouth/nose, dyspepsia, dysphagia, eructation, fecal incontinence, flatulence, hemorrhoids, gum/oral hemorrhage, [0m
[31mhematemesis, hepatocellular damage, hepatomegaly, liver function test abnormal, ileus, mucositis, rectal disorder, stomatitis, ulcerative stomatitis, and veno-occlusive liver disease. Hemic & [0m
[31mLymphatic System Anemia, coagulation disorder, ecchymosis, fluid overload, petechia, prothrombin decreased, prothrombin increased, and thrombocytopenia. AMBISOME: adverse_reactions: Metabolic & [0m
[31mNutritional Disorders Acidosis, amylase increased, hyperchloremia, hyperkalemia, hypermagnesemia, hyperphosphatemia, hyponatremia, hypophosphatemia, hypoproteinemia, lactate dehydrogenase increased, [0m
[31mnonprotein nitrogen [0m[1;31m([0m[31mNPN[0m[1;31m)[0m[31m increased, and respiratory alkalosis. Musculoskeletal System Arthralgia, bone pain, dystonia, myalgia, and rigors. Nervous System Agitation, coma, convulsion, cough, [0m
[31mdepression, dysesthesia, dizziness, hallucinations, nervousness, paresthesia, somnolence, thinking abnormality, and tremor. Respiratory System Asthma, atelectasis, hemoptysis, hiccup, [0m
[31mhyperventilation, influenza-like symptoms, lung edema, pharyngitis, pneumonia, respiratory insufficiency, respiratory failure, and sinusitis. AMBISOME: adverse_reactions: Skin & Appendages Alopecia, [0m
[31mdry skin, herpes simplex, injection site inflammation, maculopapular rash, purpura, skin discoloration, skin disorder, skin ulcer, urticaria, and vesiculobullous rash. Special Senses Conjunctivitis, [0m
[31mdry eyes, and eye hemorrhage. Urogenital System Abnormal renal function, acute kidney failure, acute renal failure, dysuria, kidney failure, toxic nephropathy, urinary incontinence, and vaginal [0m
[31mhemorrhage. Post-marketing Experience The following infrequent adverse experiences have been reported in post-marketing surveillance, in addition to those mentioned above: angioedema, erythema, [0m
[31murticaria, bronchospasm, cyanosis/hypoventilation, pulmonary edema, agranulocytosis, hemorrhagic cystitis, and rhabdomyolysis. AMBISOME: adverse_reactions: Clinical Laboratory Values The effect of Am [0m
[31mB isome on renal and hepatic function and on serum electrolytes was assessed from laboratory values measured repeatedly in Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m002[0m[31m. The frequency and magnitude of hepatic test abnormalities [0m
[31mwere similar in the Am B isome and amphotericin B groups. Nephrotoxicity was defined as creatinine values increasing [0m[1;31m100[0m[31m% or more over pretreatment levels in pediatric patients, and creatinine values [0m
[31mincreasing [0m[1;31m100[0m[31m% or more over pretreatment levels in adult patients, provided the peak creatinine concentration was > [0m[1;31m1.2[0m[31m mg/dL. Hypokalemia was defined as potassium levels â‰¤ [0m[1;31m2.5[0m[31m mmol/L any time during[0m
[31mtreatment. AMBISOME: adverse_reactions: Incidence of nephrotoxicity, mean peak serum creatinine concentration, mean change from baseline in serum creatinine, and incidence of hypokalemia in the [0m
[31mdouble-blind, randomized study were lower in the Am B isome group as summarized in the following table: Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m002[0m[31m Laboratory Evidence of Nephrotoxicity AmBisome [0m[1;31m3[0m[31m mg/kg/day Amphotericin B [0m[1;31m0.6[0m[31m [0m
[31mmg/kg/day Total number of patients receiving at least one dose of study drug [0m[1;31m343[0m[31m [0m[1;31m344[0m[31m Nephrotoxicity [0m[1;31m64[0m[31m [0m[1;31m([0m[1;31m18.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m116[0m[31m [0m[1;31m([0m[1;31m33.7[0m[31m%[0m[1;31m)[0m[31m Mean peak creatinine [0m[1;31m1.24[0m[31m mg/dL [0m[1;31m1.52[0m[31m mg/dL Mean change from baseline in [0m
[31mcreatinine [0m[1;31m0.48[0m[31m mg/dL [0m[1;31m0.77[0m[31m mg/dL Hypokalemia [0m[1;31m23[0m[31m [0m[1;31m([0m[1;31m6.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m40[0m[31m [0m[1;31m([0m[1;31m11.6[0m[31m%[0m[1;31m)[0m[31m The effect of Am B isome [0m[1;31m([0m[1;31m3[0m[31m mg/kg/day[0m[1;31m)[0m[31m vs. AMBISOME: adverse_reactions: amphotericin B [0m[1;31m([0m[1;31m0.6[0m[31m mg/kg/day[0m[1;31m)[0m[31m on renal function in adult [0m
[31mpatients enrolled in this study is illustrated in the following figure: In empirical therapy study [0m[1;31m97[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m034[0m[31m, the incidence of nephrotoxicity as measured by increases of serum creatinine from baseline [0m
[31mwas significantly lower for patients administered Am B isome [0m[1;31m([0m[31mindividual dose groups and combined[0m[1;31m)[0m[31m compared with amphotericin B lipid complex. Incidence of Nephrotoxicity Empirical Therapy Study [0m
[1;31m97[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m034[0m[31m AmBisome Amphotericin B lipid complex [0m[1;31m5[0m[31m mg/kg/day [0m[1;31m3[0m[31m mg/kg/day [0m[1;31m5[0m[31m mg/kg/day BOTH Total number of patients [0m[1;31m85[0m[31m [0m[1;31m81[0m[31m [0m[1;31m166[0m[31m [0m[1;31m78[0m[31m Number with nephrotoxicity [0m[1;31m1.[0m[31m5X baseline serum creatinine value [0m[1;31m25[0m[31m [0m[1;31m([0m[1;31m29.4[0m[31m%[0m[1;31m)[0m
[1;31m21[0m[31m [0m[1;31m([0m[1;31m25.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m46[0m[31m [0m[1;31m([0m[1;31m27.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m49[0m[31m [0m[1;31m([0m[1;31m62[0m[31m. AMBISOME: adverse_reactions: [0m[1;31m8[0m[31m%[0m[1;31m)[0m[31m 2X baseline serum creatinine value [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m14.1[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m14.8[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[1;31m14.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m33[0m[31m [0m[1;31m([0m[1;31m42.3[0m[31m%[0m[1;31m)[0m[31m The following graph shows the average serum creatinine [0m
[31mconcentrations in the compassionate use study and shows that there is a drop from pretreatment concentrations for all patients, especially those with elevated [0m[1;31m([0m[31mgreater than [0m[1;31m1.7[0m[31m mg/dL[0m[1;31m)[0m[31m pretreatment [0m
[31mcreatinine concentrations. The incidence of nephrotoxicity in Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m013[0m[31m comparative trial in cryptococcal meningitis was lower in the Am B isome groups as shown in the following table: Laboratory[0m
[31mEvidence of Nephrotoxicity Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m013[0m[31m AmBisome [0m[1;31m3[0m[31m mg/kg/day AmBisome [0m[1;31m6[0m[31m mg/kg/day Amphotericin B [0m[1;31m0[0m[31m. AMBISOME: adverse_reactions: [0m[1;31m7[0m[31m mg/kg/day Total number of patients receiving at least one dose of [0m
[31mstudy drug [0m[1;31m86[0m[31m [0m[1;31m94[0m[31m [0m[1;31m87[0m[31m Number with Nephrotoxicity [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m [0m[1;31m1[0m[31m. AMBISOME: adverse_reactions: 5X baseline serum creatinine [0m[1;31m30[0m[31m [0m[1;31m([0m[1;31m35[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m44[0m[31m [0m[1;31m([0m[1;31m47[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m52[0m[31m [0m[1;31m([0m[1;31m60[0m[31m%[0m[1;31m)[0m[31m 2X baseline serum creatinine [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m14[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m20[0m[31m [0m[1;31m([0m[1;31m21[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m29[0m[31m [0m[1;31m([0m[1;31m33[0m[31m%[0m[1;31m)[0m[31m Mean [0m
[31mChange in Creatinine Over Time in Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m002[0m[31m Mean Creatine Concentrations Over Time         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m


[31mCONTENT: AMBISOME: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: AMBISOME has been associated with renal adverse effects, including abnormal renal function, acute kidney failure, acute renal failure, and toxic nephropathy. However, in comparative studies, [0m
[32mthe incidence of nephrotoxicity was lower in patients treated with AMBISOME compared to those treated with amphotericin B or amphotericin B lipid complex. For example, in Study [0m[1;32m94[0m[32m-[0m[1;32m0[0m[32m-[0m[1;32m002[0m[32m, the incidence[0m
[32mof nephrotoxicity was [0m[1;32m18.7[0m[32m% for AMBISOME compared to [0m[1;32m33.7[0m[32m% for amphotericin B. Similarly, in empirical therapy study [0m[1;32m97[0m[32m-[0m[1;32m0[0m[32m-[0m[1;32m034[0m[32m, the incidence of nephrotoxicity was significantly lower for patients [0m
[32madministered AMBISOME compared with amphotericin B lipid complex. These findings suggest that while AMBISOME can increase the risk of renal failure, it may do so to a lesser extent than other [0m
[32mformulations of amphotericin B.[0m

[32mSOURCE: AMBISOME label[0m
[32mEXTRACT_START_END: AMBISOME: adverse_reactions: Urogenital System[0m[32m...[0m[32m AMBISOME: adverse_reactions: Incidence of nephrotoxicity[0m[32m...[0m
*[1m([0morchestrator-renal failure-AMBISOME[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: AMBISOME has been associated with renal adverse effects, including [0m
[34mabnormal renal function, acute kidney failure, acute renal failure, and toxic nephropathy. However, in comparative studies, the incidence of nephrotoxicity was lower in patients treated with AMBISOME [0m
[34mcompared to those treated with amphotericin B or amphotericin B lipid complex. For example, in Study [0m[1;34m94[0m[34m-[0m[1;34m0[0m[34m-[0m[1;34m002[0m[34m, the incidence of nephrotoxicity was [0m[1;34m18.7[0m[34m% for AMBISOME compared to [0m[1;34m33.7[0m[34m% for amphotericin[0m
[34mB. Similarly, in empirical therapy study [0m[1;34m97[0m[34m-[0m[1;34m0[0m[34m-[0m[1;34m034[0m[34m, the incidence of nephrotoxicity was significantly lower for patients administered AMBISOME compared with amphotericin B lipid complex. These findings[0m
[34msuggest that while AMBISOME can increase the risk of renal failure, it may do so to a lesser extent than other formulations of amphotericin B.[0m

[34mSOURCE: AMBISOME label[0m
[34mEXTRACT_START_END: AMBISOME: adverse_reactions: Urogenital System[0m[34m...[0m[34m AMBISOME: adverse_reactions: Incidence of nephrotoxicity[0m[34m...[0m
 [1m([0morchestrator-renal failure-AMBISOME[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-AMBISOME[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-renal failure-AMBISOME[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does AMBISOME increase or decrease the risk of renal failure?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether AMBISOME increases or decreases the risk of renal failure."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that AMBISOME has been associated with renal adverse effects, including abnormal renal function, acute kidney failure, acute renal failure, and toxic nephropathy."[0m[32m,[0m
[32m      [0m[32m"FDAHandler also noted that in comparative studies, the incidence of nephrotoxicity was lower in patients treated with AMBISOME compared to those treated with amphotericin B or amphotericin B [0m
[32mlipid complex, indicating that while AMBISOME can increase the risk of renal failure, it may do so to a lesser extent than other formulations of amphotericin B."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"AMBISOME has been associated with an increased risk of renal failure, including acute kidney failure and toxic nephropathy. However, it appears to have a lower incidence of [0m
[32mnephrotoxicity compared to other formulations of amphotericin B."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-renal failure-AMBISOME[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-renal failure-AMBISOME[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-renal failure-AMBISOME[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-renal failure-AMBISOME[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does AMBISOME increase or decrease the risk of renal failure?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether AMBISOME increases or decreases the risk of renal failure."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that AMBISOME has been associated with renal adverse effects, including abnormal renal function, acute kidney failure, acute renal failure, and toxic nephropathy."[0m[34m,[0m
[34m      [0m[34m"FDAHandler also noted that in comparative studies, the incidence of nephrotoxicity was lower in patients treated with AMBISOME compared to those treated with amphotericin B or amphotericin B [0m
[34mlipid complex, indicating that while AMBISOME can increase the risk of renal failure, it may do so to a lesser extent than other formulations of amphotericin B."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"AMBISOME has been associated with an increased risk of renal failure, including acute kidney failure and toxic nephropathy. However, it appears to have a lower incidence of [0m
[34mnephrotoxicity compared to other formulations of amphotericin B."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does AMBISOME increase or decrease the risk of renal failure?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether AMBISOME increases or decreases the risk of renal failure.[0m
[1;31m2[0m[31m. FDAHandler responded that AMBISOME has been associated with renal adverse effects, including abnormal renal function, acute kidney failure, acute renal failure, and toxic nephropathy.[0m
[1;31m3[0m[31m. FDAHandler also noted that in comparative studies, the incidence of nephrotoxicity was lower in patients treated with AMBISOME compared to those treated with amphotericin B or amphotericin B lipid [0m
[31mcomplex, indicating that while AMBISOME can increase the risk of renal failure, it may do so to a lesser extent than other formulations of amphotericin B.[0m
[31m        -----[0m
[31m        Final answer: AMBISOME has been associated with an increased risk of renal failure, including acute kidney failure and toxic nephropathy. However, it appears to have a lower incidence of [0m
[31mnephrotoxicity compared to other formulations of amphotericin B.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-renal failure-AMBISOME[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-renal failure-AMBISOME[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-renal failure-AMBISOME[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-renal failure-AMBISOME[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-renal failure-AMBISOME[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mAMBISOME has been associated with an increased risk of renal failure, including acute kidney failure and toxic nephropathy. However, it appears to have a lower incidence of nephrotoxicity compared to [0m
[32mother formulations of amphotericin B.[0m
